

Supplementary Figure 10. Analyses of the hematopoietic microenviroment in saline or 6OHDA-sympathectomized mice. (**a,b**) Representative immunofluorescence staining for Nestin-GFP$^+$ (green) endothelial cells (CD31; red), monocyte/macrophages (CD68, white) (**a**) or perivascular a-smooth muscle actin (aSMA) positive cells (white) and endothelial cells (CD31; red) (**b**) in the BM of saline or 6OHDA-treated *Nestin-gfp* mice prior 5FU injection. (**c,d**) as a,b but 12 days after 5FU injection. (**e,f**) Gating strategy for flow cytometry analyses of BM Nestin-GFP$^+$ and endothelial cells (EC) (**e**) or bone osteoblasts (Ob) (**f**). (**g**) Percentage of macrophages per femur and osteoblasts in bone in saline or 6OHDA treated *Nestin-gfp* mice 12 days after 5FU injection. (**h**) Percentage of endothelial cells, BM macrophages and Nestin-GFP$^+$ cells per femur, or osteoblasts in bone in saline or 6OHDA treated *Nestin-gfp* mice in the steady state (3 days after the last 6OHDA injection; n = 5–8). (**i**) Cell cycle analyses of Nestin-gfp cells and endothelial cells after treatment with saline (black) or ICI118551 and SR59230A (blue); n = 4–5. (**j**) Percentage of macrophages per femur and osteoblasts in bone in saline or cisplatin treated *Nestin-gfp* mice 4 weeks after transplantation of 10^6 BMNC. (n = 4). (**k**) Percentage of endothelial cells, BM macrophages and Nestin-GFP$^+$ cells per femur, or osteoblasts in bone in saline or cisplatin treated *Nestin-gfp* mice in the steady state (4 weeks after the last cisplatin injection; n = 5–7). Scale bar 50 μm